ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
Saturday, May 30, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: The ASCO 2026 poster presentation discusses the impact of depth of response on long-term clinical outcomes from a phase 1/1b study involving ficerafusp alfa and pembrolizumab for treating first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. The study's exploratory analyses from multiple expansion cohorts aim to provide insights into effective treatment strategies.
Price reaction · baseline $21.75 (2026-05-29 close) · 1 other BCAX headline(s) in the window, move may be shared
day 0 close
-5.2%
day 1 · peak
-9.7%
day 3
-6.2%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation highlights important clinical outcomes.
Exploratory analyses may lead to improved treatment strategies.
Focus on HPV-negative HNSCC is crucial for targeted therapies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Ficerafusp alfa
Phase 2 · Squamous Cell Carcinoma of Head and Neck (SCCHN)
Full Press Release Details
The post ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC) appeared first on Bicara Therapeutics .
Frequently Asked Questions
What was presented at ASCO 2026?
The presentation discussed the impact of depth of response on clinical outcomes in HNSCC.
What is ficerafusp alfa used for?
Ficerafusp alfa is used in combination with pembrolizumab for treating HPV-negative HNSCC.
What type of study was conducted?
A phase 1/1b study was conducted involving multiple expansion cohorts.
What is the focus of the study?
The study focuses on first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma.